Compare Crispr Therapeutics AG (CRSP) vs SPDR Gold Trust (GLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs SPDR Gold Trust — how do they compare? Crispr Therapeutics AG trades at $53.63 (market cap $4.88B), while SPDR Gold Trust trades at $384.85 (market cap $139.66B). The key difference: SPDR Gold Trust is far larger — about 28.6× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and SPDR Gold Trust for 74 Days on average.
| CRSP | GLD | |
|---|---|---|
Market Cap | $4.88B | $139.66B |
Volume | 2,861,747 | 9,544,773 |
Sector | Health | — |
52-Week High | $74.92 | $495.90 |
52-Week Low | $44.34 | $362.32 |
Typical Hold Time | 77 Days | 74 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
GLD, the SPDR Gold Trust ETF, trades at $384.77 with a 2.37% daily gain amid bearish technical signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate expectations, though recent weak employment data provided temporary support. Technical indicators show strong bearish momentum with moving averages signaling sell pressure, while oscillators remain neutral. The ETF is testing key resistance levels with support at $373-$377 and resistance at $380-$384.
The outlook remains cautious as gold faces headwinds from monetary policy tightening and dollar strength. While serving as a traditional inflation hedge, GLD's near-term performance depends on interest rate trajectory and safe-haven demand. Risks include further Fed hawkishness and declining institutional interest, though long-term diversification benefits persist for portfolio allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →
